Lawmakers are being urged to modernize the Food and Drug Administration’s authority to assess and approve artificial intelligence tools and health-care products.
“I have a lot of empathy and sympathy for the FDA at the moment where they’re being asked to evaluate a new technology that they’re not really designed to evaluate right now,” said Andrew Ibrahim, chief clinical officer at health care technology company Viz.ai.
The discussion arose during a House Energy and Commerce Health Subcommittee hearing Wednesday focused on the potential of artificial intelligence in health care. In response to questions from full committee leaders